Stemina Biomarker Discovery is preparing to go to market in early 2018 with its autism diagnostic test panel, the company announced recently.
According to a release, Heiner Dreismann, the former head of Roche Molecular Diagnostics, has joined Stemina’s board of directors to help with the commercialization strategy.
“Neurological disorders like autism and schizophrenia, which have historically been defined based on behavioral findings, are now recognized to be comprised of a variety of metabolic and genetic subtypes,” Stemina CEO Elizabeth Donley said in a statement. “We expect that our approach will provide important information for diagnosis and more precise treatment as well as opportunities to collaborate with drug developers on targeted therapies and clinical trials.”
Stemina’s NeuroPointDX, a metabolomics platform to diagnose, treat and develop new therapies for neurological disorders, is already being implemented in a clinical study with the Children’s Autism Metabolome Project (CAMP).